دورية أكاديمية
أعرض في EDS

Adoptive transfer of EBV specific CD8+ T cell clones can transiently control EBV infection in humanized mice.

التفاصيل البيبلوغرافية
العنوان: Adoptive transfer of EBV specific CD8+ T cell clones can transiently control EBV infection in humanized mice.
المؤلفون: Antsiferova O; Viral Immunobiology, Institute of Experimental Immunology, University of Zürich, Zürich, Switzerland., Müller A; Viral Immunobiology, Institute of Experimental Immunology, University of Zürich, Zürich, Switzerland., Rämer PC; Viral Immunobiology, Institute of Experimental Immunology, University of Zürich, Zürich, Switzerland., Chijioke O; Viral Immunobiology, Institute of Experimental Immunology, University of Zürich, Zürich, Switzerland., Chatterjee B; Viral Immunobiology, Institute of Experimental Immunology, University of Zürich, Zürich, Switzerland., Raykova A; Viral Immunobiology, Institute of Experimental Immunology, University of Zürich, Zürich, Switzerland., Planas R; Neuroimmunology and Multiple Sclerosis Research, Department of Neurology, University Hospital Zürich, Zürich, Switzerland., Sospedra M; Neuroimmunology and Multiple Sclerosis Research, Department of Neurology, University Hospital Zürich, Zürich, Switzerland., Shumilov A; Division of Pathogenesis of Virus Associated Tumors, German Cancer Research Centre (DKFZ), Heidelberg, Germany., Tsai MH; Division of Pathogenesis of Virus Associated Tumors, German Cancer Research Centre (DKFZ), Heidelberg, Germany., Delecluse HJ; Division of Pathogenesis of Virus Associated Tumors, German Cancer Research Centre (DKFZ), Heidelberg, Germany., Münz C; Viral Immunobiology, Institute of Experimental Immunology, University of Zürich, Zürich, Switzerland.
المصدر: PLoS pathogens [PLoS Pathog] 2014 Aug 28; Vol. 10 (8), pp. e1004333. Date of Electronic Publication: 2014 Aug 28 (Print Publication: 2014).
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101238921 Publication Model: eCollection Cited Medium: Internet ISSN: 1553-7374 (Electronic) Linking ISSN: 15537366 NLM ISO Abbreviation: PLoS Pathog Subsets: MEDLINE
أسماء مطبوعة: Original Publication: San Francisco, CA : Public Library of Science, c2005-
مواضيع طبية MeSH: B-Lymphocytes/*virology , Cell Transformation, Viral/*physiology , Epstein-Barr Virus Infections/*immunology , T-Lymphocytes, Cytotoxic/*immunology, Adoptive Transfer ; Animals ; CD8-Positive T-Lymphocytes/immunology ; Flow Cytometry ; Humans ; Immunohistochemistry ; Mice ; Mice, Transgenic ; Real-Time Polymerase Chain Reaction
مستخلص: Epstein Barr virus (EBV) infection expands CD8+ T cells specific for lytic antigens to high frequencies during symptomatic primary infection, and maintains these at significant numbers during persistence. Despite this, the protective function of these lytic EBV antigen-specific cytotoxic CD8+ T cells remains unclear. Here we demonstrate that lytic EBV replication does not significantly contribute to virus-induced B cell proliferation in vitro and in vivo in a mouse model with reconstituted human immune system components (huNSG mice). However, we report a trend to reduction of EBV-induced lymphoproliferation outside of lymphoid organs upon diminished lytic replication. Moreover, we could demonstrate that CD8+ T cells against the lytic EBV antigen BMLF1 can eliminate lytically replicating EBV-transformed B cells from lymphoblastoid cell lines (LCLs) and in vivo, thereby transiently controlling high viremia after adoptive transfer into EBV infected huNSG mice. These findings suggest a protective function for lytic EBV antigen-specific CD8+ T cells against EBV infection and against virus-associated tumors in extra-lymphoid organs. These specificities should be explored for EBV-specific vaccine development.
References: Blood. 2013 Jun 27;121(26):5113-23. (PMID: 23610374)
J Immunol. 2013 Dec 1;191(11):5398-409. (PMID: 24146041)
J Gen Virol. 2009 Oct;90(Pt 10):2331-2341. (PMID: 19553389)
J Immunol Methods. 2001 Dec 1;258(1-2):111-26. (PMID: 11684128)
J Virol. 2013 Feb;87(4):2011-22. (PMID: 23236073)
Nat Rev Cancer. 2004 Oct;4(10):757-68. (PMID: 15510157)
N Engl J Med. 2010 May 27;362(21):1993-2000. (PMID: 20505178)
Annu Rev Immunol. 2007;25:587-617. (PMID: 17378764)
Cancer Res. 2013 Mar 15;73(6):1676-88. (PMID: 23348421)
Cell Rep. 2013 Dec 26;5(6):1489-98. (PMID: 24360958)
Blood. 2007 Aug 15;110(4):1123-31. (PMID: 17468341)
J Immunol. 2010 Jan 1;184(1):303-14. (PMID: 19949089)
J Exp Med. 2000 May 15;191(10):1649-60. (PMID: 10811859)
J Virol. 2005 Jun;79(12):7641-7. (PMID: 15919916)
J Exp Med. 2006 Apr 17;203(4):995-1006. (PMID: 16549597)
Adv Cancer Res. 2007;97:81-109. (PMID: 17419942)
EMBO J. 2000 Jun 15;19(12):3080-9. (PMID: 10856251)
J Virol. 2004 Jan;78(2):768-78. (PMID: 14694109)
Vet Pathol. 2008 Nov;45(6):914-21. (PMID: 18984796)
Cell Rep. 2013 Feb 21;3(2):371-85. (PMID: 23416052)
PLoS One. 2007 Jul 04;2(7):e583. (PMID: 17611619)
Blood. 2008 Aug 15;112(4):1231-9. (PMID: 18519810)
J Exp Med. 1997 May 5;185(9):1605-17. (PMID: 9151898)
J Virol. 2011 Jan;85(1):165-77. (PMID: 20980506)
J Med Virol. 2001 Aug;64(4):505-12. (PMID: 11468736)
Lancet. 2002 Aug 10;360(9331):436-42. (PMID: 12241714)
J Immunol. 2005 Jun 1;174(11):6829-38. (PMID: 15905524)
J Infect Dis. 2007 Dec 15;196(12):1749-53. (PMID: 18190254)
J Exp Med. 2009 Jun 8;206(6):1423-34. (PMID: 19487422)
Vaccine. 2013 Jun 26;31(30):3039-45. (PMID: 23665339)
J Exp Med. 2005 Feb 7;201(3):349-60. (PMID: 15684323)
Cell Rep. 2013 Oct 31;5(2):458-70. (PMID: 24120866)
PLoS Pathog. 2012 Dec;8(12):e1003095. (PMID: 23300447)
J Virol. 2005 Nov;79(22):13993-4003. (PMID: 16254335)
J Exp Med. 1998 May 4;187(9):1395-402. (PMID: 9565632)
J Clin Invest. 2012 Apr;122(4):1487-502. (PMID: 22406538)
Blood. 2010 Nov 25;116(22):4700-2. (PMID: 20709906)
Blood. 2012 Mar 15;119(11):2644-56. (PMID: 22138512)
Eur J Immunol. 2013 Sep;43(9):2246-54. (PMID: 23913412)
J Virol. 2008 Apr;82(8):3903-11. (PMID: 18272580)
J Virol. 1999 Nov;73(11):9206-12. (PMID: 10516028)
Annu Rev Pathol. 2006;1:375-404. (PMID: 18039120)
Blood. 2013 Feb 28;121(9):1584-94. (PMID: 23297134)
J Virol. 2011 Dec;85(24):13105-13. (PMID: 21994444)
Blood. 2010 Nov 18;116(20):4158-67. (PMID: 20671122)
Lancet. 1995 Jan 7;345(8941):9-13. (PMID: 7799740)
J Exp Med. 1992 Jul 1;176(1):157-68. (PMID: 1319456)
Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13022-7. (PMID: 20615947)
Blood. 2013 Jun 20;121(25):5034-44. (PMID: 23482932)
J Immunol. 2012 Oct 1;189(7):3618-30. (PMID: 22942431)
معلومات مُعتمدة: United Kingdom Wellcome Trust
تواريخ الأحداث: Date Created: 20140829 Date Completed: 20150616 Latest Revision: 20211021
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC4148450
DOI: 10.1371/journal.ppat.1004333
PMID: 25165855
قاعدة البيانات: MEDLINE
الوصف
تدمد:1553-7374
DOI:10.1371/journal.ppat.1004333